RA Capital Management 13F holdings, Q3 2015
Holdings as of September 30, 2015 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 47 US equity positions worth $696.3m in its Q3 2015 13F filing. The largest position was ACHILLION PHARMACEUTICALS INC at 11.6% of the reported book, followed by AXOVANT SCIENCES LTD and DYAX CORP. Against the Q2 2015 filing, it opened 18 new positions, added to 7 and reduced 14 among the top 47 holdings.
What did RA Capital Management own in Q3 2015? Top 47 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2015 |
|---|---|---|---|---|---|---|---|
| 1 | ACHILLION PHARMACEUTICALS INC | 11.6% | $81.1m | 11,733,815 | 18% | added | |
| 2 | AXOVANT SCIENCES LTD | 9.3% | $64.6m | 5,000,000 | 0% | held | |
| 3 | DYAX CORP | 7.0% | $48.7m | 2,551,193 | -6% | reduced | |
| 4 | COLL COLLEGIUM PHARMACEUTICAL INC | Healthcare | 4.9% | $34.3m | 1,553,175 | 1% | added |
| 5 | TGTX TG THERAPEUTICS INC | Healthcare | 4.5% | $31.5m | 3,124,480 | -5% | reduced |
| 6 | REGULUS THERAPEUTICS INC | 3.8% | $26.4m | 4,039,823 | 7% | added | |
| 7 | CHRS COHERUS BIOSCIENCES INC | Healthcare | 3.8% | $26.2m | 1,305,020 | -5% | reduced |
| 8 | ASND ASCENDIS PHARMA A S | Healthcare | 3.7% | $25.9m | 1,461,268 | -24% | reduced |
| 9 | ZOGENIX INC | 3.3% | $22.7m | 1,679,500 | – | new | |
| 10 | AQUINOX PHARMACEUTICALS INC | 3.1% | $21.6m | 1,532,151 | – | new | |
| 11 | PROTEON THERAPEUTICS INC | 3.0% | $21.0m | 1,506,872 | 0% | held | |
| 12 | AIMT AIMMUNE THERAPEUTICS INC | 2.9% | $20.0m | 790,200 | – | new | |
| 13 | DICERNA PHARMACEUTICALS INC | 2.9% | $19.9m | 2,428,571 | 0% | held | |
| 14 | GLOBAL BLOOD THERAPEUTICS INC | 2.8% | $19.3m | 457,142 | – | new | |
| 15 | 2655787D BLUEPRINT MEDICINES CORP | 2.7% | $18.7m | 878,348 | 0% | held | |
| 16 | ARDX ARDELYX INC | Healthcare | 2.6% | $18.4m | 1,064,013 | -38% | reduced |
| 17 | CIDARA THERAPEUTICS INC | 2.2% | $15.0m | 1,180,570 | 3% | added | |
| 18 | BLUEBIRD BIO INC | 2.1% | $14.3m | 167,367 | 53% | added | |
| 19 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 2.0% | $13.6m | 1,196,603 | -54% | reduced |
| 20 | INTRA CELLULAR THERAPIES INC | 1.8% | $12.6m | 314,349 | – | new | |
| 21 | PRONAI THERAPEUTICS INC | 1.8% | $12.4m | 604,982 | – | new | |
| 22 | ALCOBRA LTD | 1.6% | $11.1m | 1,832,911 | 20% | added | |
| 23 | TXMD THERAPEUTICSMD INC | 1.3% | $8.9m | 1,518,460 | -10% | reduced | |
| 24 | NEURODERM LTD | 1.3% | $8.8m | 425,000 | – | new | |
| 25 | NTRA NATERA INC | Healthcare | 1.2% | $8.5m | 783,521 | – | new |
| 26 | XNCR XENCOR INC | Healthcare | 1.2% | $8.3m | 679,885 | -37% | reduced |
| 27 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 1.2% | $8.2m | 1,445,430 | 18% | added |
| 28 | TENX TENAX THERAPEUTICS INC | 1.2% | $8.0m | 2,670,300 | 0% | held | |
| 29 | NIVALIS THERAPEUTICS INC | 1.1% | $7.9m | 612,863 | -19% | reduced | |
| 30 | ZYNERBA PHARMACEUTICALS INC | 1.1% | $7.5m | 525,000 | – | new | |
| 31 | MCRB SERES THERAPEUTICS INC | Healthcare | 1.0% | $7.3m | 246,645 | 0% | held |
| 32 | AKTX AKARI THERAPEUTICS PLC | 0.9% | $6.3m | 263,921 | – | new | |
| 33 | RARE ULTRAGENYX PHARMACEUTICAL INC | Healthcare | 0.8% | $5.4m | 56,067 | – | new |
| 34 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 0.7% | $5.1m | 63,026 | – | new |
| 35 | BELLICUM PHARMACEUTICALS INC | 0.7% | $4.6m | 315,704 | -69% | reduced | |
| 36 | AGILE THERAPEUTICS INC | 0.6% | $4.3m | 630,702 | -57% | reduced | |
| 37 | ARCA BIOPHARMA INC | 0.6% | $4.0m | 811,227 | – | new | |
| 38 | VITAE PHARMACEUTICALS INC | 0.5% | $3.5m | 321,161 | – | new | |
| 39 | EPIZYME INC | 0.4% | $2.9m | 227,092 | – | new | |
| 40 | AURIS MED HLDG AG | 0.2% | $1.7m | 467,572 | -50% | reduced | |
| 41 | 2GT APPLIED GENETIC TECHNOL CORP | 0.2% | $1.6m | 121,100 | – | new | |
| 42 | NVAX NOVAVAX INC | Healthcare | 0.2% | $1.1m | 162,060 | -89% | reduced |
| 43 | VICAL INC | 0.1% | $958.0k | 2,084,078 | -20% | reduced | |
| 44 | BNTC BENITEC BIOPHARMA LTD | 0.1% | $864.0k | 140,548 | – | new | |
| 45 | DURECT CORP | 0.1% | $745.0k | 381,800 | 0% | held | |
| 46 | WAFERGEN BIO-SYSTEMS INC | 0.0% | $279.0k | 205,400 | 0% | held | |
| 47 | AMPLIPHI BIOSCIENCES CORP | 0.0% | $257.0k | 65,100 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.